EGFR and neoplasm: Presence of an IDH wild-type status and either epidermal growth factor receptor (EGFR) amplification, telomere reverse transcriptase (TERT) promoter mutations, or +7/−10 chromosomal alterations is sufficient to diagnose a tumor as GBM, even in the absence of classic histological features, including necrosis and microvascular proliferation [10].